NYSE:PEN
Penumbra Inc
Penumbra Inc. dominates the neurovascular surgical robotics market with a high-margin platform that combines advanced imaging and robotic assistance for stroke treatment.
Key Metrics
Investment Thesis
Bull Case
Investors should consider Penumbra's strong revenue CAGR and the recent establishment of consistent profitability after years of investment phase. The company's leadership in a high-barrier-to-entry niche with recurring service revenue potential offers an attractive risk-adjusted return profile compared to broader medtech peers.
Bear Case
The stock carries valuation risks due to the large accumulated deficit of $237.7M and significant other non-cash adjustments of negative $91.1M that may indicate aggressive accounting or legacy restructuring costs. Heavy reliance on a single product line and potential regulatory headwinds in international markets could limit upside if competitors successfully replicate the platform.
About Penumbra Inc
Penumbra Inc. is a leading provider of surgical robotics and smart medical devices designed to enhance patient outcomes through advanced imaging and robotic precision. The company serves hospitals and outpatient centers globally with its flagship Penumbra Neurovascular system, which enables minimally invasive treatments for stroke and vascular conditions. Revenue growth from $847M in 2022 to $1.4B in 2025 reflects strong adoption of its proprietary technology across neurovascular markets.
Analysis
Management Discussion
The company delivered a significant turnaround in profitability, with net income surging from a $2.0M loss in 2022 to $177.7M in 2025, while revenue climbed 65% over the same period. Operating cash flow of $238.7M demonstrates strong liquidity management despite heavy investing outflows of $404.6M, likely tied to strategic capacity expansion or acquisitions. The substantial accounts receivable balance of $190.0M suggests growing credit exposure as sales scale rapidly.
Industry Overview
The global surgical robotics market is expanding rapidly as hospitals adopt technology to reduce procedure times and improve surgical outcomes for complex cases like stroke interventions. Penumbra operates in a specialized segment where high switching costs and strict regulatory approval processes provide protection against price wars, though competition from established players remains a constant threat.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $847.1M | $1.06B | $1.19B | $1.40B |
| Cost of Revenue | $311.9M | $375.9M | $439.6M | $461.2M |
| Gross Profit | $535.2M | $682.6M | $755.0M | $942.4M |
| Operating Expenses | $529.1M | $609.1M | $745.7M | $753.2M |
| Operating Income | $6.1M | $73.6M | $9.3M | $189.2M |
| G&A | $449.7M | $506.5M | $574.0M | $663.4M |
| Stock-Based Comp | $37.4M | $50.5M | $46.2M | $59.2M |
| D&A | $24.3M | $27.3M | $23.7M | $17.5M |
| Amortization | $9.2M | $10.2M | $5.5M | $712.0K |
| Other OpEx | $79.4M | $102.6M | $171.7M | $89.8M |
| Non-Operating Income | $-2.2M | $6.1M | $11.6M | $15.9M |
| Interest Expense | — | $1.7M | — | — |
| Interest Income | — | $6.8M | $13.7M | $16.3M |
| Pre-Tax Income | $3.9M | $79.7M | $20.9M | $205.1M |
| Income Tax | $5.9M | $-11.3M | $6.9M | $27.4M |
| Continuing Ops | $-2.0M | $91.0M | $14.0M | $177.7M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $-2.0M | $91.0M | $14.0M | $177.7M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-2.0M | $91.0M | $14.0M | $177.7M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $755.7M | $915.4M | $951.1M | $1.22B |
| Cash & Equivalents | $69.9M | $167.5M | $324.4M | $186.9M |
| Accounts Receivable | $203.4M | $201.8M | $167.7M | $190.0M |
| Inventory | $334.0M | $388.0M | $406.7M | $431.5M |
| Prepaid Expenses | $30.3M | $36.4M | $36.6M | $50.3M |
| Other Current Assets | $118.2M | $121.7M | $15.7M | $357.9M |
| Long-Term Assets | $615.2M | $640.9M | $582.1M | $609.8M |
| PP&E (Net) | $65.0M | $72.7M | $62.6M | $117.4M |
| Intangibles | $81.2M | $71.1M | $6.5M | $6.2M |
| Goodwill | $166.0M | $166.3M | $165.8M | $166.8M |
| Operating Leases | $192.6M | $188.8M | $177.8M | $173.6M |
| Other LT Assets | $110.3M | $142.1M | $169.3M | $145.9M |
| Total Assets | $1.37B | $1.56B | $1.53B | $1.83B |
| Current Liabilities | $144.9M | $151.1M | $158.3M | $183.1M |
| Accounts Payable | $26.7M | $27.2M | $31.3M | $34.7M |
| Current Leases | $10.0M | $11.2M | $12.2M | $13.8M |
| Deferred Revenue | $9.2M | $7.0M | $940.0K | — |
| Other Current Liab | $-7.2M | $-4.8M | $1.4M | $2.4M |
| Long-Term Liabilities | $227.1M | $226.2M | $223.9M | $215.8M |
| LT Operating Leases | $199.0M | $197.2M | $187.1M | $182.8M |
| Other LT Liab | $28.1M | $29.0M | $36.8M | $33.0M |
| Total Liabilities | $372.0M | $377.4M | $382.2M | $398.9M |
| Shareholders' Equity | $998.9M | $1.18B | $1.15B | $1.43B |
| Paid-In Capital | $963.0M | $1.05B | $1.10B | $1.19B |
| Retained Earnings | $43.9M | $134.9M | $60.0M | $237.7M |
| AOCI | $-8.1M | $-3.2M | $-5.8M | $4.3M |
| Total L&E | $1.37B | $1.56B | $1.53B | $1.83B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-2.0M | $91.0M | $14.0M | $177.7M |
| Non-Cash Adjustments | $-223.3M | $-87.8M | $94.2M | $-13.7M |
| Working Capital Changes | $169.7M | $94.2M | $60.2M | $74.7M |
| Cash from Operations | $-55.7M | $97.3M | $168.5M | $238.7M |
| Capital Expenditures | $19.3M | $15.2M | $21.2M | $63.7M |
| Cash from Investing | $54.8M | $-16.1M | $77.6M | $-404.6M |
| Share Buybacks | — | — | $100.4M | $0 |
| Cash from Financing | $11.6M | $16.2M | $-87.0M | $26.5M |
| FX Effect | $-272.0K | $168.0K | $-2.2M | $1.9M |
| Net Change in Cash | $10.5M | $97.6M | $156.9M | $-137.5M |
| Beginning Cash | $59.4M | $69.9M | $167.5M | $324.4M |
| Ending Cash | $69.9M | $167.5M | $324.4M | $186.9M |
Frequently Asked Questions
How does Penumbra Inc make money?
Neurovascular Robotics (core revenue driver from Penumbra Neurovascular system), Smart Medical Devices (imaging-guided procedural tools), and Surgical Automation Solutions (integrated operating room technologies).
What are the main risks for PEN?
Intense competition from large medical device incumbents like Medtronic and Stryker potentially eroding market share, dependency on reimbursement policies that could change under new healthcare legislation, and high capital expenditure requirements to maintain R&D and manufacturing capabilities.
What is PEN's competitive advantage?
Proprietary robotic platform offering superior precision in complex neurovascular procedures, strong regulatory approvals in major markets including the US and EU, and a robust installed base of imaging-integrated devices that create switching costs for hospitals.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.